AzurRx BioPharma Receives Insititutional Review Board Approval to Commence its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
April 30, 2020 08:00 ET
|
AzurRx BioPharma, Inc.
IRB protocol approval provides green-light to initiate trial at U.S. clinical sites NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX) (“AzurRx” or the “Company”),...